Biden’s budget request for NCI would set back Sharpless’s goal of raising R01 paylines to 15%

True, President Joe Biden is proposing the largest-ever funding increase for NIH, with a substantial percentage of funds going toward cancer (The Cancer Letter, April 9, May 28, June 4, 2021).

Alas, cancer researchers who have been funded by NCI are unlikely to benefit from this windfall, should it materialize. Most of the new money—$6.5 billion—would go to the Advanced Research Projects Agency for Health, or ARPA-H, and NCI is slated to get a less-than-jaw-dropping 2.7% increase in fiscal 2022.

While 2.7% is not nothing, it will do very little to enable NCI in its efforts to wrestle the Research Project Grants payline up to the 15th percentile by 2025 (The Cancer Letter, Feb. 12, 2021). In February, NCI Director Ned Sharpless said NCI was on track to meet that goal In FY2021, but this may be knocked off track—and off the rails.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

Byline

Alexandria Carolan

Reporter

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Conversation with The Cancer Letter

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Over the past seven years, as Steven K. Libutti was designing the 12-story, $900-plus million cancer hospital in New Brunswick, NJ, he often thought of the functionality of the building that inspired it: Building 10, the NIH Clinical Center.

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models.

April 25, 2025

Vol.51 No.16

By Claire Marie Porter

Podcast

In the Headlines: What’s in Trump’s draft budget?

A confidential Trump administration budget document obtained by The Cancer Letter called for a 40% budget cut to NIH and a restructuring of the 27 existing NIH institutes and centers down to just eight. But what else is in it?

April 23, 2025

Vol.51 No.15

Podcast The Directors

The Directors: Louis Weiner and Taofeek Owonikoko on keeping up morale amid uncertainty
“We are resolute. We are committed to continuing to move the work forward.”

Speaking on The Cancer Letter Podcast, Taofeek Kunle Owonikoko recalled recent conversations with two junior faculty members at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.

April 18, 2025

Vol.51 No.15

By Paul Goldberg

Trump administration seeks to slash NIH by roughly 40% as 27 institutes and centers are whittled down to eight
NCI to remain intact, but its finances are uncertain; FDA is spared big cuts

Confidential Trump administration budget documents show that the upcoming FY26 Budget Request will radically cut about $50 billion out of the U.S. Department of Health and Human Services, reshuffling agency components, and slashing the number of NIH institutes and centers to just eight.

NCI summarizes changes to the CCSG NOFO

In an email sent to directors and deputy directors of NCI-designated cancer centers, Krzysztof Ptak, director of the NCI Office of Cancer Centers, provided a comparison between the newly issued Cancer Center Support Grant Notice of Funding Opportunity with the previous version of the document.

April 18, 2025

Vol.51 No.15

Biden’s budget request for NCI would set back Sharpless’s goal of raising R01 paylines to 15%

YOU MAY BE INTERESTED IN

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In the Headlines: What’s in Trump’s draft budget?

The Directors: Louis Weiner and Taofeek Owonikoko on keeping up morale amid uncertainty
“We are resolute. We are committed to continuing to move the work forward.”

Trump administration seeks to slash NIH by roughly 40% as 27 institutes and centers are whittled down to eight
NCI to remain intact, but its finances are uncertain; FDA is spared big cuts

NCI summarizes changes to the CCSG NOFO

Renew today!

Subscriber content

Never miss an issue!

Login

Biden’s budget request for NCI would set back Sharpless’s goal of raising R01 paylines to 15%

YOU MAY BE INTERESTED IN

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industryCommissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In the Headlines: What’s in Trump’s draft budget?

The Directors: Louis Weiner and Taofeek Owonikoko on keeping up morale amid uncertainty“We are resolute. We are committed to continuing to move the work forward.”

Trump administration seeks to slash NIH by roughly 40% as 27 institutes and centers are whittled down to eightNCI to remain intact, but its finances are uncertain; FDA is spared big cuts

NCI summarizes changes to the CCSG NOFO

Never miss an issue!

Login

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

The Directors: Louis Weiner and Taofeek Owonikoko on keeping up morale amid uncertainty
“We are resolute. We are committed to continuing to move the work forward.”

Trump administration seeks to slash NIH by roughly 40% as 27 institutes and centers are whittled down to eight
NCI to remain intact, but its finances are uncertain; FDA is spared big cuts